ESR1 and breast cancer: Endocrine manipulation is the mainstay of treatment of HR+/human epidermal growth factor 2- negative (HER2-) BC, and the traditional armamentarium includes aromatase inhibitors (AI), selective estrogen receptor modulators (SERMs, as tamoxifen), selective estrogen receptor degraders (SERDs, as fulvestrant).